Apoptosis in Huntington disease and animal models

Advances in Cell Aging and Gerontology

Volumn 6, Issue C, 2001, Pages 205-223

  Koliatsos, V E ^a   Portera Cailliau, C ^a   Schilling, G ^a   Borchelt, D B ^a   Becher, M W ^a   Ross, C A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33749425708     PISSN: 15663124     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1566-3124(01)06008-4     Document Type: Review

References (97)

1. Albin R.L., and Greenamyre J.T. Alternative excitotoxic hypotheses. Neurology 42 (1992) 733-738
2. Albin R.L., Reiner A., Anderson K.D., Dure IV L.S., Handelin B., Balfour R., Whetsell W.O., Penney J.B., and Young A.B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 31 (1992) 425-430
3. Bates G. Expanded glutamines and neurodegeneration - a gain of insight. Bioessays 18 (1996) 175-178
4. Beal M.F., Brouillet E., Jenkins B., Henshaw R., Rosen B., and Hyman B.T. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61 (1993) 1147-1150
5. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., and Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13 (1993) 4181-4192
6. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann. Neurol. 36 (1994) 882-888
7. Beal M.F., Hyman B.T., and Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?. Trends Neurosci. 16 (1993) 125-131
8. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., and Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321 (1986) 168-171
9. Bredt D.S., and Snyder S.H. Nitric oxide, a novel neuronal messenger. Neuron 8 (1992) 3-11
10. Brouillet E., Jenkins B.G., Hyman B.T., Ferrante R.J., Kowall N.W., Srivastava R., Roy D.S., Rosen B.R., and Beal M.F. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60 (1993) 356-369
11. Bruce-Keller A.J., Umberger G., McFall R., and Mattson M.P. Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann. Neurol. 45 (1999) 8-15
12. Byers R.K., and Dodge J.A. Huntington's chorea in children. Neurology 17 (1967) 587-596
13. Byers R.K., Gilles F.H., and Gung C. Huntington's disease in children: Neuropathologic study of four cases. Neurology 23 (1973) 561-561
14. Cotman C.W., Monaghan D.T., Ottersen O.P., and Storm-Mathisen J. Anatomical organization of excitatory amino acid receptors and their pathways. Trends Neurosci. 10 (1987) 273-280
15. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate & neurodegenerative disorders. Science 262 (1993) 689-695
16. Coyle J.T., and Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263 (1976) 244-246
17. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., and Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
18. Dawson V.L., Dawson T.M., Bartley D.A., Uhl G.R., and Snyder S.H. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J. Neurosci. 13 (1993) 2651-2661
19. Dawson V.L., Kizushi V.M., Huang P.L., Snyder S.H., and Dawson T.M. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. J. Neurosci. 16 (1996) 2479-2487
20. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., and Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997) 1990-1993
21. Duan W., and Mattson M.P. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. Res. 57 (1999) 195-206
22. Dugan L.L., Sensi S.L., Canzoniero L.M.T., Handran S.D., Rothman S.M., Lin T.S., Goldberg M.P., and Choi D. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J. Neurosci. 15 (1995) 6377-6388
23. Dunlap C.B. Pathologic changes in Huntington's chorea. With special reference to the corpus striatum. Arch. Neurol. Psychiatry 18 (1927) 867-943
24. Duyao M., Ambrose C., Myers R., Novelletto A., Persichetti F., Frontali M., Folstein S., Ross C., Franz M., Abbott M., Gray J., Conneally P., Young A., Penney J., Hollingsworth Z., Shoulson I., Lazzarini A., Falek A., Koroshetz W., Sax D., Bird E., Vonsattel J., Bonilla E., Alvir J., Bickham Conde J., Cha J.-H., Dure L., Gomez F., Ramos M., Sanchez-Ramos J., Snodgrass S., de Young M., Wexler N., Moscowitz C., Penchaszadeh G., MacFarlane H., Anderson M., Jenkins B., Srinidhi J., Barnes G., Gusella J., and MacDonald M. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4 (1993) 387-392
25. Fusco F.R., Chen Q., Lamoreaux W.J., Figueredo-Cardenas G., Jiao Y., Coffman J.A., Surmeier D.J., Honig M.G., Carlock L.R., and Reiner A. Cellular localization of huntingtin in striatal and cortical neruons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J. Neurosci. 19 (1999) 1189-1202
26. Gavrieli Y., Sherman Y., and Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119 (1992) 493-501
27. Gourfinkel-An I., Cancel G., Duyckaerts C., Faucheux B., Hauw J.J., Trottier Y., Brice A., Agid Y., and Hirsch E.C. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset. Neuroreport 9 (1998) 1823-1826
28. Greene J.C., and Greenamyre J.T. Manipulation of membrane potential modulates malonate-induced striatal excitotoxicity in vivo. Soc. Neurosci. Abstr. 21 (1995) 1039-1039 (Abstract)
29. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., and Schapira A.H.V. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39 (1996) 385-389
30. Guo Q., Fu W., Xie J., Luo H., Sells S.F., Geddes J.W., Bondada V., Rangnekar V.M., and Mattson M.P. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nature Med. 4 (1998) 957-962
31. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., and Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19 (1999) 2522-2534
32. Gutekunst C.-A., Levey A.I., Heilman C.J., Whaley W.L., Yi H., Nash N.R., Rees H.D., Madden J.J., and Hersch S.M. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. USA 92 (1995) 8710-8714
33. Hedreen J.C., Peyser C.E., Folstein S.E., and Ross C.A. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci. Lett. 133 (1991) 257-261
34. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., and Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23 (1999) 181-192
35. Housman D. Gain of glutamines, gain of function?. Nat. Genet. 10 (1995) 3-4
36. 28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Neuroscience 65 (1995) 397-407
37. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
38. Ignatowicz E., Vezzani A.-M., Rizzi M., and D'Incalci M. Nerve cell death induced in vivo by kainic acid and quinolinic acid does not involve apoptosis. Neuroreport 2 (1991) 651-654
39. Ikeuchi T., Koide R., Tanaka H., Onodera O., Igarashi S., Takahashi H., Kondo R., Ishikawa A., Tomoda A., Miike T., Sato K., Ihara Y., Hayabara T., Isa F., Tanabe H., Tokiguchi S., Hayashi M., Shimizu N., Ikuta F., Naito H., and Tsuji S. Dentatorubral-pallidoluysian atrophy: clinical features are closely related to unstable expansions of trinucleotide (CAG) repeat. Ann. Neurol. 37 (1995) 769-775
40. Jackson M., Gentleman S., Lennox G., Ward L., Gray T., Randall K., Morrell K., and Lowe J. The cortical neuritic pathology of Huntington's disease. Neuropathol. Appl. Neurobiol. 21 (1995) 18-26
41. Jenkins B.E., Brouillet E., Chen Y.-C., Storey E., Schulz J.B., Kirschner P., Beal M.F., and Rosen B.R. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J. Cereb. Blood Flow Metab. 16 (1996) 450-461
42. 1H NMR spectroscopy. Neurology 43 (1993) 2689-2695
43. Jervis G.A. Huntington's chorea in childhood. Arch. Neurol. 9 (1963) 244-257
44. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Brent Clark H., Zoghbi H.Y., and Orr H.T. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95 (1998) 41-53
45. Komure O., Sano A., Nishino N., Yamauchi N., Ueno S., Kondoh K., Sano N., Takahashi M., Murayama N., Kondo I., Nagafuchi S., Yamada M., and Kanazawa I. DNA analysis in hereditary dentatorubral-pallidoluysian atrophy: correlation between CAG repeat length and phenotypic variation and the molecular basis of anticipation. Neurology 45 (1995) 143-149
46. Kure S., Tominaga T., Yoshimoto T., Tada K., and Narisawa K. Glutamate triggers internucleosomal DNA cleavage in neuronal cells. Biochem. Biophys. Res. Commun. 179 (1991) 39-45
47. LaSpada A.R., Paulson H.L., and Fischbeck K.H. Trinucleotide repeat expansion in neurological disease. Ann. Neurol. 36 (1994) 814-822
48. Li X.-J., Li S.-H., Sharp A.H., Nucifora Jr. F.C., Schilling G., Lanahan A., Worley P., Snyder S.H., and Ross C.A. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378 (1995) 398-402
49. Logroscino G., Marder K., Cote L., Tang M.X., Shea S., and Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann. Neurol. 39 (1996) 89-94
50. Ludolph A.C., He F., Spencer P.S., Hammerstad J., and Sabri M. 3-nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18 (1991) 492-498
51. MacDonald M.E., and Gusella J.F. Huntington's disease: Translating a CAG repeat into a pathogenic mechanism. Curr. Op. Neurobiol. (1997) (In Press)
52. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
53. Mattson M.P. Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. Trends Neurosci. 21 (1998) 53-57
54. Mayeux R., Costa R., Bell K., Merchant C., Tung M.X., and Jacobs D. Reduced risk of Alzheimer's disease among individuals with low calorie intake. Neurology 59 (1999) S296-S297
55. McCaughey W.T.E. The pathologic spectrum of Huntington's chorea. J. Nerv. Ment. Dis. 133 (1961) 91-103
56. McGeer E.G., and McGeer P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 263 (1976) 517-519
57. McGeer E.G., McGeer P.L., and Singh K. Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract. Brain Res. 139 (1978) 381-383
58. 3H]glutamate-binding sites in rat brain. J. Neurosci. 5 (1985) 2909-2919
59. Monaghan D.T., Bridges R.J., and Cotman C. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 29 (1989) 365-402
60. Nakai M., Qin Z.H., Chen J.F., Wang Y., and Chase T.N. Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation. J. Neurochem. 74 (2000) 647-658
61. Nasir J., Goldberg Y.P., and Hayden M.R. Huntington disease: New insights into the relationship between CAG expansion and disease. Hum. Mol. Genet. 5 (1996) 1431-1435
62. Nelson J.S. Diseases of the basal ganglia. In: Ducket S. (Ed). Pediatric Neuropathology (1995), Williams & Wilkins, Baltimore 212-214
63. Obeid L.M., Linardic C.M., Karolak L.A., and Hannun Y.A. Programmed cell death induced by ceramide. Science 259 (1993) 1769-1771
64. Olney J.W., and Ishimaru M.J. Excitotoxic cell death. In: Koliatsos V.E., and Ratan R.R. (Eds). Cell death and diseases of the nervous system (1998), Humana Press, Totowa 197-220
65. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E., Yuan J., Penney J.B., Young A.B., Cha J.H., and Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399 (1999) 263-267
66. Oppenheimer D.R., and Esiri M.M. Diseases of the basal ganglia, cerebellum and motor neurons. In: Adams J.H., and Duchen L.W. (Eds). Greenfield's Neuropathology (1992), Oxford University Press, New York 988-1045
67. Peitsch M.C., Polzar B., Stephan H., Crompton T., MacDonald H.R., Mannherz H.G., and Tschopp J. Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis (programmed cell death). EMBO J. 12 (1993) 371-377
68. Persichetti F., Ambrose C.M., Ge P., McNeil S.M., Srinidhi J., Anderson M.A., Jenkins B., Barnes G.T., Duyao M.P., Kanaley L., Wexler N.S., Myers R.H., Bird E.D., Vonsattel J.-P., MacDonald M.E., and Gusella J.F. Normal and expanded Huntington's disease gene alleles produce distinguishable proteins due to translation across the CAG repeat. Mol. Med. 1 (1995) 374-383
69. Perutz M. Polar zippers: their role in human disease. Protein Sci. 3 (1994) 1629-1637
70. Portera-Cailliau C., Hedreen J.C., Price D.L., and Koliatsos V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15 (1995) 3775-3787
71. Portera-Cailliau C., Sung C.-H., Nathans J., and Adler R. Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa. Proc. Natl. Acad. Sci. USA 91 (1994) 974-978
72. Rabacchi S.A., Bonfanti L., Liu X.-H., and Maffei L. Apoptotic cell death induced by optic nerve lesion in the neonatal rat. J. Neurosci. 14 (1994) 5292-5301
73. Reddy P.H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell Jr. W.O., Miller G., and Tagle D.A. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 20 (1998) 198-202
74. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., and Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. USA 85 (1988) 5733-5737
75. Rodda R.A. Cerebellar atrophy in Huntington's disease. J. Neurol. Sci. 50 (1981) 147-157
76. Rosenow F., Herholz K., Lanfermann H., Weuthen G., Ebner R., Kessler J., Ghaemi M., and Heiss W.-D. Neurological sequelae of cyanide intoxication- the patterns of clinical, magnetic resonance imaging, and positron emission tomography findings. Ann. Neurol. 38 (1995) 825-828
77. Ross C.A., Margolis R.L., Becher M.W., Wood J.D., Engelender S., and Sharp A.H. Pathogenesis of polyglutamine neurodegenerative diseases: towards a unifying mechanism. In: Wells R.D., and Warren S.T. (Eds). Genetic Instabilities and Hereditary Neurological Diseases (1997), Academic Press, Inc, New York
78. Ross C.A. When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Neuron 15 (1995) 493-496
79. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G.P., Davies S.W., Lehrach H., and Wanker E.E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90 (1997) 549-558
80. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., Copeland N.G., Price D.L., Ross C.A., and Borchelt D.R. Intranuclear inclusions and neuritic pathology in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8 (1999) 397-407
81. Schulz J.B., Henshaw D.R., Siwek D., Jenkins B.G., Ferrante R.J., Cipolloni P.B., Kowall N.W., Rosen B.R., and Beal M.F. Involvement of free radicals in excitotoxicity in vivo. J. Neurochem. 64 (1995) 2239-2247
82. Schulz J.B., Huang P.L., Matthews R.T., Passov D., Fishman M.C., and Beal M.F. Striatal malonate lesions are attenuated in neuronal nitric oxide synthase knockout mice. J. Neurochem. 67 (1996) 430-433
83. Schulz J.B., Matthews R.T., Jenkins B.G., Ferrante R.J., Siwek D., Henshaw D.R., Cipolloni P.B., Mecocci P., Kowall N.W., Rosen B.R., and Beal M.F. Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. J. Neurosci. 15 (1995) 8419-8429
84. Schulz J.B., Matthews R.T., Henshaw D.R., and Beal M.F. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 71 (1996) 1043-1048
85. Sharp A.H., and Ross C.A. Neurobiology of Huntington's disease. Neurobiol. Dis. 3 (1996) 3-15
86. Sharp A.H., Loev S.J., Schilling G., Li S.-H., Li X.-J., Bao J., Wagster M.V., Kotzuk J.A., Steiner J.P., Lo A., Hedreen J., Sisodia S., Snyder S.H., Dawson T.M., Ryugo D.K., and Ross C.A. Widespread expression of the Huntington's disease gene (IT-15) protein product. Neuron 14 (1995) 1065-1074
87. Snell R.G., MacMillan J.C., Cheadle J.P., Fenton I., Lazarou L.P., Davies P., MacDonald M.E., Gusella J.F., Harper P.S., and Shaw D.J. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 4 (1993) 393-397
88. Stine O.C., Pleasant N., Franz M.L., Abbott M.H., Folstein S.E., and Ross C.A. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum. Mol. Genet. 2 (1993) 1547-1549
89. Taylor-Robinson S.D., Weeks R.A., Bryant D.J., Sargentoni J., Marcus C.D., Harding A.E., and Brooks D.J. Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxic theory?. Mov. Disord. 11 (1996) 167-173
90. Uitti R.J., Rajput A.H., Ashengurst E.M., and Rozdilsky B. Cyanide-induced parkinsonism: a clinicopathologic report. Neurology 35 (1985) 921-925
91. Vonsattel J.-P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., and Richardson Jr. E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44 (1985) 559-577
92. Wanker E.E., Rovira C., Scherzinger E., Hasenbank R., Walter S., Tait D., Colicelli J., and Lebrach H. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6 (1997) 487-495
93. Warren S., and Nelson D.L. Trinucleotide repeat expansions in neurological disease. Curr. Opin. Neurobiol. 3 (1993) 752-759
94. Wilcox B.J., Applegate M.D., Portera-Cailliau C., and Koliatsos V.E. Nerve growth factor prevents apoptotic cell death in injured central cholinergic neurons. J. Comp. Neurol. 359 (1995) 573-585
95. Young A.B., and Fagg G.E. Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches. Trends Pharmacol. Sci. 11 (1990) 126-133
96. Young A.B., Greenamyre J.T., Hollingsworth Z., Albin R., D'Amato C., Shoulson I., and Penney J.B. NMDA receptor losses in putamen from patients with Huntington's disease. Science 241 (1988) 981-983
97. Zhu H., Guo Q., and Mattson M.P. Dietary restriction protects hippocampal neurons against the death-promoting action of a presenilin-1 mutation. Brain Res. 842 (1999) 224-229